WntResearch announces that the last patient has been treated in a Phase 1b study with the drug candidate Foxy-5
WntResearch today announced that all patients have now finalized the treatment in the expansion group of a Phase 1b study with the drug candidate Foxy-5, developed to prevent metastases in patients with certain common types of cancer. Hence, the Phase 1b study is now completed and the company can continue the planning of a randomized Phase 2 study with Foxy-5.Preliminary results from the dose-finding part of the study showed that Foxy-5 has a favorable safety profile and provides clear signals of biological effect. Based on these positive results, a dose level was selected for evaluation in